SCHEMBL3318635

SCHEMBL3318635

N[C@@H]1CCCC[C@@H]1c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 9/20 0.60
KDM1A O60341 9/20 0.60
MAOA P21397 7/20 0.60
CYP2C19 P33261 4/20 0.60
CYP2B6 P20813 3/20 0.60
CYP1A2 P05177 2/20 0.60
CYP2D6 P10635 2/20 0.60
CYP2C9 P11712 2/20 0.60
LMNA P02545 2/20 0.60
TAAR1 Q96RJ0 2/20 0.60
CYP3A4 P08684 1/20 0.60
HTR1A P08908 1/20 0.60
ADRA2A P08913 1/20 0.60
CYP2A6 P11509 1/20 0.60
SLC6A2 P23975 1/20 0.60
HTR2C P28335 1/20 0.60
ADRA1A P35348 1/20 0.60
DRD3 P35462 1/20 0.60
SLC6A3 Q01959 1/20 0.60
KCNH2 Q12809 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4041525 1.00 MAOB (0.60) MAOBKDM1AMAOACYP2C19CYP2B6
SCHEMBL445956 1.00 MAOB (0.60) MAOBKDM1AMAOACYP2C19CYP2B6
SCHEMBL12261925 1.00 MAOB (0.60) MAOBKDM1AMAOACYP2C19CYP2B6
SCHEMBL13479566 1.00 MAOB (0.60) MAOBKDM1AMAOACYP2C19CYP2B6
SCHEMBL15165363 1.00 MAOB (0.60) MAOBKDM1AMAOACYP2C19CYP2B6
SCHEMBL10494836 1.00 MAOB (0.60) MAOBKDM1AMAOACYP2C19CYP2B6
Hydrochloric Acid SCHEMBL7315925 0.98 MAOB (0.61) MAOBKDM1AMAOACYP2C19CYP2B6
Hydrochloric Acid SCHEMBL7315927 0.98 MAOB (0.61) MAOBKDM1AMAOACYP2C19CYP2B6
SCHEMBL29265379 0.98 MAOB (0.58) MAOBKDM1AMAOACYP2C19CYP2B6
SCHEMBL29087266 0.98 MAOB (0.58) MAOBKDM1AMAOACYP2C19CYP2B6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2888265-B1 BIVALENT INHIBITORS OF IAP PROTEINS AND THERAPEUTIC METHODS USING THE SAME UNIV MICHIGAN REGENTS (US) 2017-10-11 EP disclosed
US-8389511-B2 Bicyclic heterocyclic derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-03-05 US disclosed
US-8367696-B2 Aza-bridged-ring compound ASTELLAS PHARMA INC. (JP) 2013-02-05 US disclosed
US-20110190278-A1 BICYCLIC HETEROCYCLIC DERIVATIVE DAINIPPON SUMITOMO PHARMA CO. 2011-08-04 US disclosed
US-20100105658-A1 AZA-BRIDGED-RING COMPOUND ASTELLAS PHARMA INC. (JP) 2010-04-29 US disclosed
EP-2119716-A1 AZA-BRIDGED-RING COMPOUND Astellas Pharma Inc. (JP) 2009-11-18 EP disclosed
EP-0900207-B1 PYRAZINONE THROMBIN INHIBITORS MERCK & CO INC (US) 2001-11-21 EP disclosed
EP-0900207-A1 PYRAZINONE THROMBIN INHIBITORS Merck & Co., Inc. (US) 1999-03-10 EP disclosed
US-5866573-A Pyrazinone thrombin inhibitors MERCK & CO., INC. (US) 1999-02-02 US disclosed
WO-1997040024-A1 PYRAZINONE THROMBIN INHIBITORS MERCK & CO., INC. (US) 1997-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190278-A1 BICYCLIC HETEROCYCLIC DERIVATIVE REN, AGTR1, AGTR2 MAOB 30/4885KDM1A 1455/4885MAOA 87/4885
US-20100105658-A1 AZA-BRIDGED-RING COMPOUND CHRM3, CHRM1, CHRM2 MAOB 1241/4885KDM1A 326/4885MAOA 908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.